Novartis chases Roche's oncology crown
This article was originally published in Scrip
Executive Summary
Novartis, which has grown rapidly since the start of the decade to become the second biggest pharmaceutical company in the oncology arena in terms of sales, hopes to catch up over time to its cross-town rival Roche, it said during a recent oncology and pipeline update for investors.